Prometheus Bio Appoints Mike Walther as Chief Commercial Officer

Mike Walther has been appointed chief commercial officer of Prometheus Biosciences, which is developing new gastroenterology and autoimmune disease drugs and diagnostics. Walther was most recently general manager at Aries Pharmaceuticals. His experience also includes a series of management roles, including vice president of commercial development, at Nestlé Health Science unit Prometheus Laboratories. The conglomerate’s health-science division this summer sold Prometheus Labs to Precision IBD, which subsequently renamed itself Prometheus Bio.

Prometheus Bio also announced Monday that it has appointed Chris Slavinsky, a Takeda Pharmaceutical (NYSE: [[ticker:TAK]]) vice president, to serve as general counsel and head of business development. Before Takeda, Slavinsky did a 17-year stretch at Pfizer (NYSE: [[ticker:PFE]]).

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.